The IPPN is delighted by today‘s FDA approval of afamelanotide, a significant milestone in a long, too long, and challenging journey to give EPP patients access to this life-changing therapy. While afamelanotide‘s manufacturer plans for distribution and works to secure reimbursement in the US, the approval is already a great achievement for EPP patients in the US and beyond. The IPPN hopes that it will provide momentum in accelerating access to many more patients worldwide and commits to further contributing to this goal.
For now, let us savor the moment!